Carboplatin NDC 61703-262

NDC codes

FDA NDC Directory

Product NDC (as listed)61703-262Labeler and product segments. Claims need a package NDC.

Product NDC at billing width61703-0262Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
61703-262-05	61703026205	1 VIAL, MULTI-DOSE in 1 CARTON (61703-262-05) / 45 mL in 1 VIAL, MULTI-DOSEMarketed from May 23, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Carboplatin
Generic name (nonproprietary): carboplatin
Active ingredients: Carboplatin — 10 mg/mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Hospira, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076517
Marketing start: May 23, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Platinum-containing Compounds (EXT)
Identifiers: Product ID 61703-262_5aa72c15-8033-4559-b257-373371b18958SPL ID 5aa72c15-8033-4559-b257-373371b18958SPL set ID 47677091-fd20-49af-933c-c9dd2be21de9RxCUI 597195UNII BG3F62OND5
Pharmacologic class: Platinum-based Drug

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N461703026205 followed by a unit qualifier and the quantity

Package 61703-0262-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 21, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of Carboplatin Injection and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) becau…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 076517

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 076517
Product	Strength	Form · route	Labeler	Product NDC
Carboplatin	Carboplatin 10 mg/mL	Injection, SolutionIntravenous	Hospira, Inc.	61703-150
Carboplatin	Carboplatin 10 mg/mL	Injection, SolutionIntravenous	Hospira, Inc.	61703-339
Carboplatin	Carboplatin 10 mg/mL	Injection, SolutionIntravenous	Hospira, Inc.	61703-360